Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
1367
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2026-07-02
ImmuneOnco Receives NMPA IND Approval for IMM2510S Subcutaneous Formulation
More
2026-07-01
ImmuneOnco Biopharmaceuticals Appoints Ms. Ben Xiao as Senior Vice President of Investment and Financing
More
2026-06-26
ImmuneOnco Named Among Top 100 in R&D; Secures Dual Spots on the 2026 China Pharmaceutical R&D Strength Ranking
More

For more information

Please follow the official wechat public account